Background: The present study was designed to describe the clinical profile of acute exacerbations of chronic obstructive pulmonary disease (COPD) and the treatment prescribed by primary care physicians (PCPs) in Spain. Method: An observational, multicenter and cross-sectional study was performed in patients diagnosed with acute exacerbation of COPD and treated by PCPs. Patients diagnosed with asthma, cystic fibrosis, significant bronchiectasis or pneumonia were not included in the study. Results: A total of 329 general physicians recruited 1088 evaluable patients across the country. Mean age was 66.5±10.2 years; male : female ratio was 3 : 1. Spirometry was performed in 28.3% of the patients. The number of acute exacerbations in the last year was 3.3±2.5; 88.7% had increased expectoration, 87.5% increased dyspnea, 64.4% increased sputum purulence, and 43.5% fever. A total of 6.1% (n ¼ 59) of patients were hospitalized due to exacerbation. The most frequently prescribed medications were antibiotics (84.5%, n ¼ 919), mucolytic agents (72.5%, n ¼ 789), inhaled corticosteroids (ICs) (71.3%, n ¼ 776), and short-acting beta-adrenergic drugs (67.8%, n ¼ 738). Oral corticosteroids were prescribed to 436 patients (40.1%).
Introduction
Chronic obstructive pulmonary disease (COPD) constitutes a major public health problem. COPD is a major cause of morbidity and mortality in the industrialized world and results in substantial healthcare costs in both the outpatient and hospital settings associated with direct medical care costs as well as indirect costs from sick leave and days lost from work [Mannino, 2002] .
Acute exacerbation in COPD (AECOPD) is frequent in the course of the illness and is the most common reason for medical visits, hospital admissions and mortality among these patients, with an average of 1.92.1 episodes per year in patients with moderate disease [Brunton et al. 2004; Burge et al. 2000; Paggiaro et al. 1998 ].
The number of past AECOPD episodes is one of the best predictors of the risk of suffering acute exacerbations in the future [Miravitlles et al. 2000 ]. Other factors associated with the presence of relapses include the severity of the underlying disease, increased age, and failure to use oxygen therapy in the home when indicated [Miravitlles et al. 2001 ]. Thus, one of the main objectives in the management of COPD is to reduce the number and severity of acute exacerbations [Rabe et al. 2007; Snow et al. 2001a Snow et al. , 2001b .
The objective of the present study was to describe the clinical profile and management of AECOPD in a large cohort of patients in the primary care (PC) setting in Spain.
Patients and methods
A multicenter, cross-sectional observational study was designed to examine the clinical profile of acute exacerbations and treatment of patients with COPD in Spain. The patients were evaluated in a PC setting. A total of 329 general practitioners from throughout Spain participated in the study. In the period between May and October 2004, we recruited patients of either sex who were at least 40 years of age with a diagnosis of COPD who experienced an exacerbation [Barbera et al. 2001 ].
Exacerbation was defined as sustained worsening of the patient's condition from stable state characterized by the increase of any combination of three cardinal symptoms: dyspnea, sputum purulence, and sputum volume [Anthonisen et al. 1987] . Patients diagnosed with asthma, cystic fibrosis, significant bronchiectasis, or pneumonia were not included.
Each investigator recruited four consecutive patients from outpatient clinics. COPD was defined by forced expiration volume in 1 second (FEV 1 )/forced vital capacity (FVC) ratio less than 0.7 [Rabe et al. 2007 ]. The severity of COPD was classified according to the GOLD criteria (mild COPD if FEV 1 was 80%, moderate between 50% and 80%, and severe if FEV 1 below 50%). If spirometry was unavailable, COPD was diagnosed by the presence of key clinical symptoms defined in the GOLD guidelines such chronic tobacco/smoke exposure, chronic cough, sputum production and/or dyspnea [Rabe et al. 2007 ].
Data were collected at the time of study from the onset of respiratory symptoms. Bacteriologic data were not collected because in Spain, as in many countries, it is not regular practice to collect a sputum sample in a primary care physician (PCP) setting. Demographic characteristics (age, sex, weight, height) were obtained, along with general clinical parameters (comorbidities and current medications).
Smoking status at the time of the study was documented. In the case of former smokers we determined the date that the patient quit. We also recorded whether the patients had prior pulmonary function tests. In those cases where no lung function tests had been obtained, we evaluated the reasons for failing to do so. We recorded: years since diagnosis, main respiratory symptoms, total number of AECOPD episodes, visits to PCP or emergency department, number of hospital admissions in the previous 12 months, and use of healthcare resources.
Seasonal flu and pneumococcal vaccinations were recorded. The current treatment regimen and the use of noninvasive mechanical ventilation were also recorded. We documented the treatment prescribed. The clinical severity of acute exacerbation was scored according to the number of symptoms: increased dyspnea, sputum production, and purulence [Anthonisen et al. 1987 ]. Patients with one symptom were considered to have a mild exacerbation, two symptoms a moderate exacerbation, and three or more as cases of severe acute exacerbation [Anthonisen et al. 1987] . Comparisons were made of the clinical and treatment characteristics according to the severity of AECOPD.
Statistical analyses were performed using the SPSS version 15.0 statistical package, (SPSS, Chicago, IL). Descriptive analyses included calculation of the mean and standard deviation (SD) for quantitative variables, and frequencies and percentages for qualitative variables. Percentages were compared with the chi-squared test. Comparisons of means were performed with parametric and nonparametric tests.
The study was approved by the Clinical Research Ethics Committee of the Teknon Medical Center in Barcelona (Spain). All patients gave written informed consent prior to inclusion in the study, in abidance with the principles of the Declaration of Helsinki.
Results
A total of 1207 patients were recruited. Of these, 1088 met the inclusion criteria and were therefore included in the analyses. Demographic characteristics and comorbidities of the patients are shown in Table 1 . The mean age (SD) was 66.5 (10.3) years; 75.6% were males. Seventy eight percent had comorbidities, with systemic arterial hypertension the most prevalent (47.8%). The baseline clinical characteristics of stable-phase COPD are described in Table 2 . The mean disease duration was 10.6 (7.2) years.
Predominant symptoms were dyspnea (94.9%), cough (85.9%), and expectoration (75.7%). The mean number of acute exacerbations in the Therapeutic Advances in Respiratory Disease 4 (4) previous year was 3.3 (2.5). Spirometry had been performed in 308 subjects (28.3%). The classification of COPD severity by spirometry was established in 258 patients (23.7%).
The reasons for the low percentage of performed spirometry were: (1) nonavailability of spirometry (64.1%, n ¼ 500), (2) clinical diagnosis of COPD at the time of the study (16.9%, n ¼ 132), and (3) spirometry testing was not common clinical practice in the center (6.7%, n ¼ 52). The cause was not specified in 96 subjects (8.8%).
There were 22.2% (n ¼ 239) current smokers and 4.2% (n = 481) of total patients quit at least 6 months before visit. In 13.1% of cases, the patient reported not being a smoker. Patients averaged 24 pack-years of tobacco use. Patient smoking characteristics are presented in Figure 1 . Eighty nine percent of patients were taking COPD medications in the stable phase of the disease (Table 3) . Ninetysix percent of patients were prescribed inhaled drugs. Respiratory therapy was documented in 21% and 12% were prescribed with chronic oxygen therapy.
Ninety-three percent of the patients received flu vaccination and 55.6% received pneumococcal vaccine. Nonmechanical ventilation was documented in 8.7% of patients. Number of AECOPD treated in the Emergency Department was 1.2 (SD 1.9). Number of admissions to the hospital because of exacerbation of COPD was 0.5 (0.9) and visits to PCP for AECOPD averaged 6 (5) in the past year.
Regarding current exacerbations, the onset of symptoms was 3.2 (2.5) days. Clinical characteristics of AECOPD are shown in Figure 2 . Clinical symptoms were increased expectoration in 88.7%, increased dyspnea in 87.5%, increased sputum purulence in 64.4%, and fever in 43.5%
Ex-smoker (<6 months) (n =104) 12.4%
Mean packs/year = 24
The percentages of smokers and ex-smokers were calculated with respect to the total evaluable patients (n = 1088). Thirteen patients (1.2%) did not contribute the information.
The percentages relating to the categories within the nonsmokers were calculated with respect to the total patients of this group (n =836). Inhaled corticoids n (%) 670 (61.6) Long-action beta-adrenergic drugs n (%) 663 (60.9) Long-action anticholinergic drugs n 378 (34.7) Short-action beta-adrenergic drugs n (%) 314 (28.9) Short-action anticholinergic drugs n (%) 149 (13.7)
The same patient could have more than one treatment simultaneously. Percentages calculated with respect to the total evaluable patients (n ¼ 1088).
at the time of the visit. Treatments received during AECOPD are shown in The same patient could have more than one treatment simultaneously. Percentages calculated with respect to the total evaluable patients (n ¼ 1088). mucolytic agents and 436 (40.1%) oral corticosteroids. Respiratory therapy was part of the treatment in 27.9% of patients.
The severity of AECOPD was mild in 6.2% (n ¼ 57) patients, moderate in 28.8% (n ¼ 263) and severe in 64.9% (n ¼ 592) (Table 5) . As expected, the study documented that patients with severe exacerbation had more severe disease and used more healthcare resources. The percentage of patients receiving treatment was significantly higher among subjects with severe acute exacerbation, specifically in oral medications: 96.6% (n ¼ 566) received antibiotics, 90.6% (n ¼ 445), mucolytic agents, and 69.7% (n ¼ 276) oral corticosteroids (Table 5 ).
Discussion
This has study has documented the profile of AECOPD treated by PCPs in Spain involving a large cohort of patients. AECOPD was characterized by shortness of breath and increased sputum production followed by the presence of purulent sputum and fever. Most patients had a severe exacerbation (64.9%) and had been evaluated in an outpatient clinic after the first week of symptoms. Hospital admission was necessary in a little over 5% of cases, consistent with previous observations [MacNee, 2003] .
A large majority of patients in our study had usual clinical features of chronic bronchitis (dyspnea 95%, cough 86%, and expectoration in 76%). One conclusion can be that respiratory infections in patients having pure emphysema may be not identified by PCPs as AECOPD and, hence, were not recruited.
We found that 22% of individuals were current smokers in our study. Only 44.7% quit smoking 6 Therapeutic Advances in Respiratory Disease 4 (4) months or more before the actual encounter. We have no data regarding whether active smokers had more exacerbations compared with former smokers. Our findings, with two thirds or the patients being current smokers or quitting a few months before the visit, may demonstrate the difficulty of quitting in the COPD population independent of the level of severity [Brunton et al. 2004] . One explanation may be that people with above average difficulty quitting are more prone to develop COPD. As COPD is a preventable disease, it is very important to adopt preventive measures to decrease the incidence of tobacco use and help patients quit smoking, since smoking cessation programs constitute the major key point for controlling COPD and its exacerbations. Specific tailored programs should be explored for this population [Van Schayck and Kaper, 2006; Fagerstrom, 2005] .
Another preventive factor is seasonal vaccination. Influenza vaccination has been shown to reduce the risk of disease exacerbation, while pneumococcal vaccination can reduce the incidence of complications in the form of infections [Brunton et al. 2004; Wedzicha, 2003, Macnee and Calverley, 2003] . In this context, our data show flu vaccination to be a common practice (93% of patients were vaccinated for seasonal flu), while pneumococcal vaccination was carried out in a little over 50%. Implementing guidelines regarding pneumococcal vaccination (and revaccination) in COPD may be of interest in the PC setting.
Decreasing the number of exacerbations seems warranted. Our study was performed in a PC setting where the majority of the patients are treated with antibiotics (85%) consistent with previous reports in the Spanish population [Viejo-Banuelos et al. 2006; Miravitlles et al. 1999a ].
In stable COPD, inhaled corticoids (ICs) were the most frequently prescribed drugs, together with long-acting beta-adrenergic inhalers and mucolytic agents. The treatments were similar to those reported by Miravitlles and coworkers [Miravitlles et al. 1999b ]. However, mucolytic agents were highly prescribed (41.6% in stable phase and up to 72.5% throughout an acute exacerbation), although current studies either question their efficacy or mention only scant benefit from their use [Braman, 2006] . Mucolytics are prescribed commonly in Spain. Important differences in percentage use have been reported among different countries.
Current recommendations suggest that mucolytic agents should not be recommended for acute exacerbations, although there may be benefit in more severe cases [Braman, 2006; Poole and Black, 2001] . Our results reflect increased mucolytic use in more symptomatic cases, although overall the use may be regarded as excessive considering the existing published evidence [Miravitlles et al. 1999b ].
The main difference between our findings and earlier studies is the use of less theophylline in our study: 18.8% in stable and 20.8% in AECOPD respectively versus 50% reported in the literature [Miravitlles et al. 1999b ]. This may be explained by the increased use of longacting beta-adrenergic drugs, which are more adequate for managing COPD and involve a lower risk of side effects [Taccola et al. 1999 ].
The use of anticholinergic drugs in our population remains low in patients with COPD, although is a central pillar in COPD treatment.
We found that 34.7% and 13.7% of patients used long-acting anticholinergics (tiotropium) and short-acting anticholinergics (ipratropium), respectively. The prescription of the new drug tiotropium in only one third of patients was much lower than that of ICs (61.6%). This fact can be explained because this drug was released in Spain in 2003, and it took several months to be covered by the National Institute of Health. Our data were collected in 2004 and hence may affect these results, although the use of only 13.7% in short-acting anticholinergics supports our hypothesis that these drugs are under-prescribed in a PCP setting, and may reflect poor use of current COPD guidelines.
Treatment was provided during the acute exacerbation episodes in the majority of patients. The most common were antibiotics (84.5%), mucolytics (72.5%), oral corticosteroids (40%), and ICs (71.3%). These percentages are consistent with published data [Miravitlles et al. 1999b ]. The existing evidence does not justify the extensive and widespread use of antibiotic treatment. Although such therapy is indicated in severe AECOPD, it is questionable in patients with mild or moderate exacerbation [Puhan et al. 2007 ]. In our study, there were a greater proportion of patients having severe exacerbation treated with antibiotics. The most common antibiotics used were betalactams/betalactamase inhibitors and macrolides. We already know that no clear benefit has been postulated from prescribing pulmonary rehabilitation during an acute exacerbation [Braman, 2006] .
In patients with increased sputum production, physiotherapy has been shown to offer efficacy in eliminating secretions, without causing undesirable effects upon oxygen saturation [Bellone et al. 2000 ]. In our series, approximately one third of patients were prescribed with pulmonary physiotherapy, up to 40% in the more severe cases. Of note, pulmonary rehabilitation should be prescribed only in stable phases of COPD until new data become available.
One of the most important limitations in our study is the low percentage of patients who had pulmonary function tests to establish a diagnosis of COPD. Our findings are consistent with other published studies demonstrating an insufficient use of spirometry for lung evaluation. In this context, studies published to date in the PC offices generally report pulmonary function study rates from 15% to 50% [Miravitlles et al. 2009 [Miravitlles et al. , 1999a [Miravitlles et al. , 1999b . These data may reflect the limited availability of spirometry in PC centers. Indeed, 64% of our cases fit into this category. An additional factor is the lack of training in spirometry use, as recently evidenced by a survey of 839 general practitioners in Spain in which only 59.2% of the PC centers performed spirometry on a regular basis [Naberan et al. 2006 ]. One important observation is the low number of lung function tests performed in females (17%). This may be due to the low level of awareness in this population and common misunderstanding in the medical community about COPD among females. COPD should be suspected in women exposed to tobacco [Miravitlles et al. 2007 [Miravitlles et al. , 2002 . Our findings strongly point out the need for improvement in the use of spirometry in the PC setting as a reliable, simple method to evaluate lung function and accurately diagnose COPD. We have no prospective follow up of patients in our study.
In general, all of the patients received treatment for the AECOPD. However, prevention strategies such as intensive tobacco dependence programs or an accurate characterization of chronic lung disease were far than optimal. Acute exacerbations have become a priority in international guidelines for COPD management since exacerbations are linked to quality of life, pulmonary function impairment, and overall mortality [Rabe et al. 2007 ]. In conclusion, our results document characteristics of AECOPD in a nonselected population in Spain treated by PCPs. Patients with smoke exposure at risk for COPD are not currently well characterized and should be evaluated by spirometry. The misuse of therapies and diagnostic techniques available in COPD patients highlights the necessity for closer relationships between PCPs and pulmonary specialists to better serve and treat this severe and impaired population and to follow the current guidelines of treatment of COPD and AECOPD.
